Dr. Philip Toleikis

Dr. Philip Toleikis is a senior pharmaceutical executive with extensive experience in strategic planning, technology evaluation, and R&D management. As the Chief Technology Officer and President & CEO at Sernova Corp., Dr. Philip has demonstrated their expertise in building infrastructure, establishing research priorities, and directing development programs from inception through clinical study. With a background in pharmacology and therapeutics, Dr. Toleikis has also held leadership roles at Angiotech Pharmaceuticals, Inc. where Dr. Philip oversaw R&D product development programs and corporate strategies. Their academic qualifications include a PhD in Medicine, Pharmacology & Therapeutics, an MS in Environmental Physiology, and a BA in Zoology/Animal Biology/Physiology.